BioVie says Phase 2 SUNRISE-PD trial shows bezisterim improves motor and non-motor symptoms in early Parkinson’s disease

Reuters2026/08/06 11:36

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BioVie reported topline Phase 2 SUNRISE-PD results for bezisterim in early Parkinson’s disease.
Results have been announced now; a detailed review is scheduled for an Aug. 12, 2026 conference call.
Patients on bezisterim showed broader clinical improvement versus placebo across motor function, daily activities, and non-motor symptoms.
Biomarker readouts pointed to reduced inflammation with signals consistent with potential neuroprotective effects.
Safety profile was comparable to placebo, supporting plans to use the data to shape a potential Phase 3 study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001520138-26-000312), on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BioVie says Phase 2 SUNRISE-PD trial shows bezisterim improves motor and non-motor symptoms in early Parkinson’s disease

You may also like

Crypto prices